Show simple item record

dc.contributor.authorZhang, Haojian
dc.contributor.authorLi, Huawei
dc.contributor.authorXi, Hualin S.
dc.contributor.authorLi, Shaoguang
dc.date2022-08-11T08:08:54.000
dc.date.accessioned2022-08-23T16:11:49Z
dc.date.available2022-08-23T16:11:49Z
dc.date.issued2012-03-15
dc.date.submitted2012-08-29
dc.identifier.citationBlood. 2012 Mar 15;119(11):2595-607. Epub 2012 Jan 24. doi: 10.1182/blood-2011-10-387381
dc.identifier.issn1528-0020
dc.identifier.doi10.1182/blood-2011-10-387381
dc.identifier.pmid22275380
dc.identifier.urihttp://hdl.handle.net/20.500.14038/33257
dc.description.abstractHypoxia-inducible factor-1α (HIF1α), a master transcriptional regulator of the cellular and systemic hypoxia response, is essential for the maintenance of self-renewal capacity of normal HSCs. It is still unknown whether HIF1α has a role in survival regulation of leukemia stem cells (LSCs) in chronic myeloid leukemia (CML). Using a mouse model of CML, here we report that HIF1α plays a crucial role in survival maintenance of LSCs. Deletion of HIF1α impairs the propagation of CML through impairing cell-cycle progression and inducing apoptosis of LSCs. Deletion of HIF1α results in elevated expression of p16(Ink4a) and p19(Arf) in LSCs, and knockdown of p16(Ink4a) and p19(Arf) rescues the defective colony-forming ability of HIF1α(-/-) LSCs. Compared with normal HSCs, LSCs appear to be more dependent on the HIF1α pathway. Together, these results demonstrate that HIF1α represents a critical pathway in LSCs and inhibition of the HIF1α pathway provides a therapeutic strategy for eradicating LSCs in CML.
dc.language.isoen_US
dc.publisherAmerican Society of Hematology
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22275380&dopt=Abstract">Link to article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311277/
dc.subjectAnimals
dc.subjectAnoxia
dc.subjectApoptosis
dc.subjectBiological Markers
dc.subjectBlotting, Western
dc.subjectBone Marrow Transplantation
dc.subjectCell Cycle
dc.subjectCell Proliferation
dc.subjectCyclin-Dependent Kinase Inhibitor p16
dc.subjectFlow Cytometry
dc.subjectGene Expression Profiling
dc.subjectHypoxia-Inducible Factor 1, alpha Subunit
dc.subjectLeukemia, Myelogenous, Chronic, BCR-ABL Positive
dc.subjectMice
dc.subjectMice, Inbred C57BL
dc.subjectMice, Knockout
dc.subjectNeoplastic Stem Cells
dc.subjectOligonucleotide Array Sequence Analysis
dc.subjectRNA, Messenger
dc.subjectReal-Time Polymerase Chain Reaction
dc.subjectReverse Transcriptase Polymerase Chain Reaction
dc.subjectSurvival Rate
dc.subjectUMCCTS funding
dc.subjectCancer Biology
dc.subjectHematology
dc.titleHIF1α is required for survival maintenance of chronic myeloid leukemia stem cells
dc.typeJournal Article
dc.source.journaltitleBlood
dc.source.volume119
dc.source.issue11
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/gsbs_sp/1790
dc.identifier.contextkey3273988
html.description.abstract<p>Hypoxia-inducible factor-1α (HIF1α), a master transcriptional regulator of the cellular and systemic hypoxia response, is essential for the maintenance of self-renewal capacity of normal HSCs. It is still unknown whether HIF1α has a role in survival regulation of leukemia stem cells (LSCs) in chronic myeloid leukemia (CML). Using a mouse model of CML, here we report that HIF1α plays a crucial role in survival maintenance of LSCs. Deletion of HIF1α impairs the propagation of CML through impairing cell-cycle progression and inducing apoptosis of LSCs. Deletion of HIF1α results in elevated expression of p16(Ink4a) and p19(Arf) in LSCs, and knockdown of p16(Ink4a) and p19(Arf) rescues the defective colony-forming ability of HIF1α(-/-) LSCs. Compared with normal HSCs, LSCs appear to be more dependent on the HIF1α pathway. Together, these results demonstrate that HIF1α represents a critical pathway in LSCs and inhibition of the HIF1α pathway provides a therapeutic strategy for eradicating LSCs in CML.</p>
dc.identifier.submissionpathgsbs_sp/1790
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.contributor.departmentDepartment of Medicine, Division of Hematology/Oncology
dc.source.pages2595-607
dc.contributor.studentHaojian Zhang


This item appears in the following Collection(s)

Show simple item record